肥満治療の市場規模、シェア、成長分析：手術タイプ別、薬物タイプ別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

肥満治療の世界市場規模は2023年に93億9,000万米ドルとなり、予測期間（2025-2032年）のCAGRは3.3%で、2024年の97億米ドルから2032年には125億8,000万米ドルに成長する見通しです。

世界の肥満治療市場は、糖尿病、心血管疾患、特定のがんなど、肥満とそれに関連する健康リスクの蔓延がエスカレートしているため、急成長を遂げています。この急成長は、座りがちなライフスタイル、食生活の乱れ、遺伝的要因によるところが大きいです。その結果、効果的な肥満治療に対する緊急の需要が生じています。この市場の主要プレーヤーには、食欲を抑えたりエネルギー消費を高めたりすることで体重減少を補助する承認済みの医薬品を提供する製薬会社が含まれます。さらに、肥満手術や胃バルーンなどの医療機器のような外科的オプションは、体重管理の取り組みを強化します。生活習慣の改善も重要な役割を果たしています。このダイナミックなセクターは、肥満の流行と効果的に闘うために、イノベーション、投資、ヘルスケア利害関係者間の協力のための大きな機会を提供しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩

肥満治療市場規模：手術タイプ別& CAGR（2025-2032）

• 市場概要
• 十二指腸スイッチによる胆膵バイパス術（BPD/DS）
• 胃バンディングの調整
• ルーワイ胃バイパス術
• スリーブ状胃切除術
• 内視鏡手術

肥満治療市場規模：薬物タイプ& CAGR（2025-2032）

• 市場概要
• 食欲抑制剤
• 併用薬
• 吸収不良
• 満腹薬

肥満治療市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• クリニック
• 美容機関
• その他

肥満治療市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Novo Nordisk（Denmark）
• Eli Lilly and Company（United States）
• Roche（Switzerland）
• GlaxoSmithKline（GSK）（United Kingdom）
• AstraZeneca（United Kingdom）
• Johnson & Johnson（United States）
• Sanofi（France）
• Pfizer（United States）
• Amgen（United States）
• Boehringer Ingelheim（Germany）
• Medtronic（Ireland）
• Altimmune（United States）
• Viking Therapeutics（United States）
• Structure Therapeutics（United States）
• NovoCure（United States）
• Arena Pharmaceuticals（United States）
• Rhythm Pharmaceuticals（United States）
• Zafgen（United States）
• Vivus（United States）

結論と推奨事項

Global Obesity Treatment Market size was valued at USD 9.39 billion in 2023 and is poised to grow from USD 9.7 billion in 2024 to USD 12.58 billion by 2032, growing at a CAGR of 3.3% during the forecast period (2025-2032).

The global obesity treatment market is experiencing rapid growth due to the escalating prevalence of obesity and its associated health risks including diabetes, cardiovascular diseases, and specific cancers. This surge is largely attributed to sedentary lifestyles, poor dietary choices, and genetic factors. As a result, there's an urgent demand for effective obesity interventions. Key players in this market include pharmaceutical companies offering approved medications that aid weight loss by suppressing appetite or enhancing energy expenditure. Additionally, surgical options like bariatric surgery and medical devices such as gastric balloons enhance weight management efforts. Lifestyle modifications play a crucial role as well. This dynamic sector presents substantial opportunities for innovation, investment, and collaboration among healthcare stakeholders to combat the obesity epidemic effectively.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Obesity Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Obesity Treatment Market Segmental Analysis

Global Obesity Treatment Market is segmented by Surgery Type, Drug Type, End User and region. Based on Surgery Type, the market is segmented into Biliopancreatic diversion with Duodenal Switch (BPD/DS), Adjusting Gastric Banding, Roux-en-Y Gastric Bypass, Sleeve gastrectomy and Endoscopic Procedures. Based on Drug Type, the market is segmented into Appetite suppressants, Combination drugs, Malabsorption and Satiety drugs. Based on End User, the market is segmented into Hospital, Clinics, Beauty institutions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Obesity Treatment Market

The global obesity treatment market is significantly propelled by the alarming increase in obesity rates worldwide. Contributing factors include sedentary lifestyles, poor dietary choices, and genetic tendencies, all of which have intensified this public health crisis. As the prevalence of obesity continues to rise, so does the urgency for effective treatment options aimed at mitigating the associated health risks. This pressing need is fostering a greater demand for innovative obesity treatment solutions, pushing the market forward and creating opportunities for new therapies and programs that can effectively combat this escalating issue.

Restraints in the Global Obesity Treatment Market

The Global Obesity Treatment market faces significant restraints due to the limited or sometimes nonexistent insurance coverage for obesity-related therapies. Many insurance providers impose strict eligibility criteria for coverage, such as requiring individuals to meet specific Body Mass Index (BMI) thresholds or to prove unsuccessful attempts at previous weight loss methods. This restrictive insurance landscape can severely limit access to essential treatments, leading to challenges in managing obesity effectively. As a result, individuals may struggle to obtain the care they need, undermining efforts to combat obesity on a broader scale and potentially reducing the overall success rates of treatment programs.

Market Trends of the Global Obesity Treatment Market

The Global Obesity Treatment market is witnessing a significant trend towards personalized medicine, driven by the recognition of obesity as a multifaceted condition influenced by genetic and metabolic variations. Recent advancements in genomic research and biomarker identification are facilitating the creation of tailored therapies that align with individual patient profiles. This shift not only enhances the efficacy of treatments but also encourages patient adherence, setting the stage for a new wave of precision medications and targeted interventions. As healthcare providers increasingly embrace this customized approach, the market is poised for growth, underscoring the importance of understanding individual differences in obesity management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Obesity Treatment Market Size by Surgery Type & CAGR (2025-2032)

• Market Overview
• Biliopancreatic diversion with Duodenal Switch (BPD/DS)
• Adjusting Gastric Banding
• Roux-en-Y Gastric Bypass
• Sleeve gastrectomy
• Endoscopic Procedures

Global Obesity Treatment Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Appetite suppressants
• Combination drugs
• Malabsorption
• Satiety drugs

Global Obesity Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital
• Clinics
• Beauty institutions
• Others

Global Obesity Treatment Market Size & CAGR (2025-2032)

• North America (Surgery Type, Drug Type, End User)
  • US
  • Canada
• Europe (Surgery Type, Drug Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Surgery Type, Drug Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Surgery Type, Drug Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Surgery Type, Drug Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altimmune (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viking Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Structure Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NovoCure (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arena Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zafgen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vivus (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations